Sevabertinib

塞伐艾替尼

Report date: 2026/05/20 17:55:45
NME

Base Information

Drug NameSevabertinib
Drug Alias NameHyrnuo赫新诺BAY-2927088
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursHepatic InsufficiencyLiver Diseases +[5] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2025/11/19
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBayer AGBroad InstituteHarvard University
China Registration ClassN/A

Develop Information

Active CompaniesPatheon Uk LtdBayer AGBayer Healthcare Pharmaceuticals Llc +[5] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursHepatic InsufficiencyLiver Diseases +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG